All News

Cancer often lasts far longer than from diagnosis to remission.

The BTK inhibitor Imbruvica (ibrutinib) was granted a supplemental new drug application (sNDA) by the Food and Drug Administration for the treatment of patients with chronic graft-versus-host-disease (cGVHD).

PARP inhibitors like Rubraca and Lynparza continue to shape the treatment landscape of ovarian cancer.

Patients with glioblastoma multiforme (GBM) saw a 37 percent reduced risk of death and increased overall survival (OS) when treated with tumor treating fields (TTFields), according to a landmark analysis of the findings from the EF-14 trial.

Is it possible to actually get good at living with our disease?

A survivor shares her words of wisdom.

Opdivo (nivolumab) showed better long-term survival rates than expected for patients with metastatic non-small cell lung cancer (NSCLC).

In a recent study, people with certain disabilities were found to be less likely to follow recommended guidelines for colorectal cancer screening.

Formulating a plan and knowing how to react can help to ease emotions at a difficult time in life.

Playing the cancer card, if you haven't done it yet, more than likely you will soon.

Cancer survivor discusses interviewing for jobs and returning to employment after surviving breast cancer and melanoma.

Daily or weekly aspirin regimens may have a positive effect on colorectal cancer outcomes, a recent study found.

The amount of sleep a man gets can have an impact on prostate cancer outcomes, according to a recent study.

The results of phase 3 FLAURA trial could potentially change the treatment paradigm for some patients with lung cancer.

Almost from the very beginning, I had heard the words “new normal.” The doctors, my friends, other survivors would all say, “this is your new normal.” What? I don’t get it. I don’t want cancer to be my new normal.

With cancer, every visit to the hospital is an exercise in accepting change.

Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial.

After a diagnosis of triple-negative breast cancer, Bekah Cunningham went to have a fertility preservation procedure, which ended up discovering another cancer in her lungs.

Ibrance gained full FDA approval for the treatment of some patients with breast cancer.

Fewer people are dying from cancer than years ago, according to a recent study.

Mutations might be the answer as to why sidedness has an effect on colorectal cancer outcomes.

A debate among health care providers has ensued over the cardiotoxicity risk that is associated with anthracycline regimens for patients with breast cancer. Sara A. Hurvitz, M.D., weighs in.

An ongoing trial is seeking to find out if a patient with an MPN can improve their health status through nutritional interventions.

Tagrisso (osimertinib) was granted a regular Food and Drug Administration (FDA) approval to treat some patients with lung cancer.

Some patients experience fatigue as a side effect of cancer treatment. And for some of us, fatigue lingers on and on and on.

Sometimes life is about learning to enjoy those little moments despite all the rest.

Andre Goy, M.D., discusses some exciting advances in mantle cell lymphoma (MCL).

When someone faces a cancer diagnosis during the period of social maturation, the impacts can be lasting, according to a recent study.

What role will immunotherapy play in the future treatment of GI cancers? CURE spoke to Brian Hemphill, M.D., to find out.